In the midst of an obesity assessment, the World Health Organization warns that Wegovy and other weight-loss drugs are "not silver bullets."

The World Health Organization has cautioned that new weight reduction medications will not be a "silver bullet" in the fight against obesity.

According to Francesco Branca, WHO's head of food and nutrition safety, weight reduction medicines must be taken in conjunction with a healthy diet and exercise.

Ms Branca's remarks come as the health organization launches its first revision of obesity management recommendations in over two decades.

Semaglutide, sold as Wegovy by Novo Nordisk, is an appetite suppression medication that has been licensed by the UK medicines regulation and has been characterized by some as a "game changer" in helping individuals lose weight.

Wegovy will be made available through the NHS in England to some obese persons. According to one research, patients who took the medicine lost 12% of their body weight after 68 weeks. The WHO is revising guidelines for managing obesity in children and adolescents, as well as updating advice for adults. The Mario Negri Institute for Pharmacological Research will evaluate the data for all medications used in children and adolescents.

Obesity has grown dramatically among children and adolescents aged 5 to 19 since 1975.